EP3766882A4 - Phthalazinisoxazol-alkoxyderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und ihre verwendung - Google Patents

Phthalazinisoxazol-alkoxyderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und ihre verwendung Download PDF

Info

Publication number: EP3766882A4
Authority: EP; European Patent Office
Prior art keywords: phthalazine; isoxazole; manufacturing; pharmaceutical composition; alcoxy
Prior art date: 2018-03-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP19766771.0A

Other languages

English (en)

French (fr)

Other versions

EP3766882B1 (de

EP3766882A1 (de

Inventor

Fei Wang

Jinhua Wu

Yun Jin

Yong Sun

Shuai LI

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai SIMR Biotechnology Co Ltd

Original Assignee

Shanghai SIMR Biotechnology Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-12

Filing date

2019-03-12

Publication date

2021-10-20

2019-03-12 Application filed by Shanghai SIMR Biotechnology Co Ltd filed Critical Shanghai SIMR Biotechnology Co Ltd

2021-01-20 Publication of EP3766882A1 publication Critical patent/EP3766882A1/de

2021-10-20 Publication of EP3766882A4 publication Critical patent/EP3766882A4/de

2023-08-23 Application granted granted Critical

2023-08-23 Publication of EP3766882B1 publication Critical patent/EP3766882B1/de

Status Active legal-status Critical Current

2039-03-12 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EP19766771.0A 2018-03-12 2019-03-12 Phthalazinisoxazol-alkoxyderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und ihre verwendung Active EP3766882B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201810198971		2018-03-12
PCT/CN2019/077846 WO2019174577A1 (zh)	2018-03-12	2019-03-12	酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途

Publications (3)

Publication Number	Publication Date
EP3766882A1 EP3766882A1 (de)	2021-01-20
EP3766882A4 true EP3766882A4 (de)	2021-10-20
EP3766882B1 EP3766882B1 (de)	2023-08-23

Family

ID=67907315

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19766771.0A Active EP3766882B1 (de)	2018-03-12	2019-03-12	Phthalazinisoxazol-alkoxyderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und ihre verwendung

Country Status (7)

Country	Link
US (1)	US11512089B2 (de)
EP (1)	EP3766882B1 (de)
JP (1)	JP7351590B2 (de)
CN (1)	CN110256440B (de)
AU (1)	AU2019233183B2 (de)
ES (1)	ES2964534T3 (de)
WO (1)	WO2019174577A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112979655A (zh) *	2019-12-16	2021-06-18	上海赛默罗生物科技有限公司	三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN114591352B (zh) *	2022-05-11	2022-09-09	上海赛默罗生物科技有限公司	一种三唑并哒嗪类化合物及其应用
CN114773352B (zh) *	2022-06-20	2023-03-17	上海赛默罗生物科技有限公司	制备取代的烟酰胺的方法
CN115286636A (zh) *	2022-10-08	2022-11-04	上海赛默罗生物科技有限公司	烟酰胺晶型及其制备方法和用途
CN116008442B (zh) *	2023-03-27	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116008443B (zh) *	2023-03-28	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂类药物中有关物质的检测方法
CN116046958B (zh) *	2023-03-28	2023-07-07	上海赛默罗生物科技有限公司	酞嗪异噁唑类药物中有关物质的检测方法
CN116077459B (zh) *	2023-04-10	2023-07-07	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的胶囊剂及其制备方法
CN116098870B (zh) *	2023-04-10	2023-07-25	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的固体分散体及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998050385A1 (en) *	1997-05-08	1998-11-12	Merck Sharp & Dohme Limited	SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
WO1999006407A1 (en) *	1997-07-29	1999-02-11	Merck Sharp & Dohme Limited	THERAPEUTICALLY ACTIVE 1,2,4-TRIAZOLO(4.,3-b) PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
WO2001034603A2 (en) *	1999-11-12	2001-05-17	Neurogen Corporation	Bicyclic and tricyclic heteroaromatic compounds
WO2002042305A1 (en) *	2000-11-23	2002-05-30	Merck Sharp & Dohme Limited	Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition
CN106854207A (zh) *	2015-12-08	2017-06-16	上海赛默罗生物科技有限公司	呔嗪类衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9112504D0 (en)	1991-06-11	1991-07-31	Merck Sharp & Dohme	Cell line
ES2296064T3 (es)	1992-12-10	2008-04-16	MERCK SHARP & DOHME LIMITED	Lineas celulares transfectadas de manera estable que expresan receptores gaba-a humanos con una combinacion de subunidades alfa-2, beta-3 y gamma-2.
US10206921B2 (en)	2009-06-03	2019-02-19	The Regents Of The University Of California	Methods and compositions for treating a subject for central nervous system (CNS) injury
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain

2019
- 2019-03-12 AU AU2019233183A patent/AU2019233183B2/en active Active
- 2019-03-12 EP EP19766771.0A patent/EP3766882B1/de active Active
- 2019-03-12 ES ES19766771T patent/ES2964534T3/es active Active
- 2019-03-12 US US16/979,926 patent/US11512089B2/en active Active
- 2019-03-12 CN CN201910185735.9A patent/CN110256440B/zh active Active
- 2019-03-12 JP JP2020572597A patent/JP7351590B2/ja active Active
- 2019-03-12 WO PCT/CN2019/077846 patent/WO2019174577A1/zh not_active Ceased

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998050385A1 (en) *	1997-05-08	1998-11-12	Merck Sharp & Dohme Limited	SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
WO1999006407A1 (en) *	1997-07-29	1999-02-11	Merck Sharp & Dohme Limited	THERAPEUTICALLY ACTIVE 1,2,4-TRIAZOLO(4.,3-b) PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
WO2001034603A2 (en) *	1999-11-12	2001-05-17	Neurogen Corporation	Bicyclic and tricyclic heteroaromatic compounds
WO2002042305A1 (en) *	2000-11-23	2002-05-30	Merck Sharp & Dohme Limited	Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition
CN106854207A (zh) *	2015-12-08	2017-06-16	上海赛默罗生物科技有限公司	呔嗪类衍生物、其制备方法、药物组合物和用途
EP3388433A1 (de) *	2015-12-08	2018-10-17	Shanghai Simr Biotech Co., Ltd	Phthalazinderivate und herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEBSACK A D ET AL: "Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the @a"2@d-1 subunit of voltage gated calcium channel", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 10, 17 May 2004 (2004-05-17), pages 2463 - 2467, XP004841221, ISSN: 0960-894X *

Also Published As

Publication number	Publication date
ES2964534T3 (es)	2024-04-08
CN110256440A (zh)	2019-09-20
US20210009598A1 (en)	2021-01-14
WO2019174577A1 (zh)	2019-09-19
AU2019233183B2 (en)	2024-02-01
JP7351590B2 (ja)	2023-09-27
EP3766882B1 (de)	2023-08-23
AU2019233183A1 (en)	2020-10-22
US11512089B2 (en)	2022-11-29
JP2021518425A (ja)	2021-08-02
EP3766882A1 (de)	2021-01-20
CN110256440B (zh)	2023-05-23

Legal Events

Date	Code	Title	Description
2019-09-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-12-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-12-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-01-20	17P	Request for examination filed	Effective date: 20201012
2021-01-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-01-20	AX	Request for extension of the european patent	Extension state: BA ME
2021-06-16	DAV	Request for validation of the european patent (deleted)
2021-06-16	DAX	Request for extension of the european patent (deleted)
2021-10-20	A4	Supplementary search report drawn up and despatched	Effective date: 20210921
2021-10-20	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 29/00 20060101ALI20210915BHEP Ipc: A61P 25/28 20060101ALI20210915BHEP Ipc: A61P 9/00 20060101ALI20210915BHEP Ipc: A61K 31/5377 20060101ALI20210915BHEP Ipc: A61K 31/502 20060101ALI20210915BHEP Ipc: C07D 519/00 20060101ALI20210915BHEP Ipc: C07D 487/04 20060101AFI20210915BHEP
2022-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-08-24	17Q	First examination report despatched	Effective date: 20220722
2023-03-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-03-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-04-19	INTG	Intention to grant announced	Effective date: 20230323
2023-04-19	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD Owner name: SHANGHAI SIMR BIOTECHNOLOGY CO., LTD.
2023-07-18	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-07-21	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-07-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-08-23	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-08-23	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-09-13	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-09-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602019035661 Country of ref document: DE
2023-11-22	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2023-12-11	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2023-12-20	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20231109
2024-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1602495 Country of ref document: AT Kind code of ref document: T Effective date: 20230823
2024-01-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231124
2024-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231223
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231226 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231123 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231223 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231124 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-04-08	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2964534 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240408
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-05-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602019035661 Country of ref document: DE
2024-06-27	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-06-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-07-31	26N	No opposition filed	Effective date: 20240524
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-11-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-11-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240312
2024-11-20	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240312 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2024-12-16	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20240331
2025-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240331
2025-01-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240312
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240312 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240331
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250416 Year of fee payment: 7
2025-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20250331 Year of fee payment: 7
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250401 Year of fee payment: 7
2025-08-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20190312
2025-09-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20190312
2025-12-12	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230823
2026-04-01	REG	Reference to a national code	Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260401
2026-04-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20260302 Year of fee payment: 8
2026-04-13	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20260320 Year of fee payment: 8
2026-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20260303 Year of fee payment: 8
2026-04-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20260303 Year of fee payment: 8

Publication	Publication Date	Title
EP3854877A4 (de)	2022-10-12	Modifizierte t-zelle, verfahren zu ihrer herstellung und ihre verwendung
EP3790903A4 (de)	2022-06-08	Vollmenschliche antikörper gegen ox40, verfahren zu ihrer herstellung und ihre verwendung
EP4053152A4 (de)	2023-11-15	Keratin bd-13, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3670511A4 (de)	2020-09-02	Tetrahydroprotoberberinverbindung, verfahren zu ihrer herstellung und ihre verwendung sowie pharmazeutische zusammensetzung
EP3825322C0 (de)	2024-03-20	Polypeptidverbindung, pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung davon
EP3850674C0 (de)	2023-06-07	Einzelphotonen-avalanche-detektor, verfahren zur verwendung davon und verfahren zu dessen herstellung
EP3690002A4 (de)	2021-06-23	Fluoreszierende sonde, verfahren zu ihrer herstellung und ihre verwendung
EP3858818A4 (de)	2022-06-15	Triketonverbindung, verfahren zu ihrer herstellung und ihre verwendung sowie herbizid
EP3845528C0 (de)	2023-10-11	Pyrazolverbindungen, pharmazeutische zusammensetzungen davon und ihre verwendung als irak4 inhibitoren
EP3760191A4 (de)	2021-05-05	Pharmazeutische zusammensetzung, herstellungsverfahren dafür sowie verwendung davon
EP4066861A4 (de)	2023-12-27	Polyethylenglykolkonjugatmedikament, verfahren zu seiner herstellung und seine verwendung
EP4053159A4 (de)	2023-11-29	Keratin bd-6, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
BRPI0915862A2 (pt)	2015-11-03	compostos derivados de tetraidrocinolina, processo para sua fabricação, composição farmacêutica que os compreende, uso dos mesmos e método para o tratamento ou profilaxia de diabetes e outras enfermidades
EP4039687A4 (de)	2023-10-04	Tetracyclische pyrimidinonverbindung, verfahren zu ihrer herstellung, zusammensetzung und ihre verwendung
EP3678485C0 (de)	2023-06-28	Flüssigladezusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
EP3902569C0 (de)	2025-09-24	Behandlungsindikator, verfahren zu dessen herstellung und dessen verwendung
EP4045087A4 (de)	2024-03-27	Polymerkonjugate zur arzneimittelabgabe sowie verfahren zu ihrer herstellung und verwendung
EP3929182A4 (de)	2022-06-22	Multitarget-kinasehemmer, pharmazeutische zusammensetzung damit sowie herstellungsverfahren und verwendung davon
EP4041022A4 (de)	2023-11-01	Nicht-tierische weichgelkapselformulierungen, verfahren zu ihrer herstellung und ihre verwendung
EP3705480C0 (de)	2024-02-28	Klasse von aminosubstituierten stickstoffhaltigen kondensierten ringverbindungen, verfahren zu ihrer herstellung und ihre verwendung
EP3929181A4 (de)	2022-10-26	6-oxo-1,6-dihydropyridazin-prodrug-derivate, verfahren zu ihrer herstellung und ihre verwendung in der medizin
EP3843670C0 (de)	2026-02-11	Daumenschiene und verfahren zu ihrer herstellung
EP4026566C0 (de)	2024-07-31	Orale pharmazeutische zusammensetzung mit teriparatid und verfahren zu ihrer herstellung
EP3915978A4 (de)	2022-10-26	N-benzyl-n-arylsulfonamidderivate, ihre herstellung und verwendung
EP4105216B1 (de)	2026-05-20	Dihydronaphthyridinonverbindung, verfahren zu ihrer herstellung und medizinische verwendung davon